Drug Price Trends for NDC 72205-0145

Average Pharmacy Cost for 72205-0145

Drug Name	NDC	Price/Unit ($)	Unit	Date
FAMOTIDINE 20 MG TABLET	72205-0145-05	0.03030	EACH	2026-03-18
FAMOTIDINE 20 MG TABLET	72205-0145-91	0.03030	EACH	2026-03-18
FAMOTIDINE 20 MG TABLET	72205-0145-99	0.03030	EACH	2026-03-18
FAMOTIDINE 20 MG TABLET	72205-0145-30	0.03030	EACH	2026-03-18

Best Wholesale Price for NDC 72205-0145

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for Leqvio (Inclisiran)

Last updated: February 18, 2026

This analysis examines the market landscape and price projections for Leqvio (inclisiran), a novel small interfering RNA (siRNA) therapeutic for hypercholesterolemia. Leqvio targets PCSK9, a key regulator of LDL cholesterol, offering a new mechanism of action with infrequent dosing. The analysis focuses on its market penetration, competitive positioning, and anticipated price trajectory, considering its unique value proposition and the evolving treatment paradigm.

What is the current market status of Leqvio?

Leqvio, marketed by Novartis, received its initial U.S. Food and Drug Administration (FDA) approval in December 2020 for the treatment of adults with elevated low-density lipoprotein cholesterol (LDL-C). It is indicated as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering.

The drug's therapeutic mechanism involves inhibiting the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the liver. PCSK9 is a protein that promotes the degradation of LDL receptors on liver cells. By reducing PCSK9 levels, inclisiran increases the number of LDL receptors available to clear LDL-C from the bloodstream.

Leqvio is administered via subcutaneous injection. The recommended dosage regimen is an initial dose, a second dose at 3 months, and then a maintenance dose every 6 months thereafter. This infrequent dosing schedule represents a significant departure from the daily oral medications and bi-weekly or monthly injectable biologics typically used for advanced lipid management.

As of late 2023 and early 2024, Leqvio has achieved commercialization and is actively being prescribed. Its market penetration is influenced by physician adoption, patient access, and formulary coverage by payers. The initial uptake has been steady, with efforts by Novartis focusing on educating healthcare providers about the drug's efficacy and administration profile.

The competitive landscape for LDL-C lowering agents includes a range of therapies. These include:

• Statins: The cornerstone of lipid-lowering therapy, available as generics.
• Ezetimibe: A cholesterol absorption inhibitor, often used in combination with statins.
• PCSK9 Inhibitors (Monoclonal Antibodies): Alirocumab (Praluent) and evolocumab (Repatha) are injectable biologics that directly inhibit PCSK9. These are administered every two to four weeks.
• Bile Acid Sequestrants: Older medications with a generally less potent LDL-C lowering effect and potential gastrointestinal side effects.
• Fibrates and Niacin: Primarily used for triglyceride management and HDL-C elevation, with less direct impact on LDL-C.

Leqvio's differentiation lies in its siRNA mechanism and infrequent dosing, offering a potentially more convenient and adherent treatment option for patients who require additional LDL-C reduction beyond statin therapy, or for those who are statin-intolerant. The drug's safety profile, as demonstrated in clinical trials, has also been a key factor in its market introduction.

What is the clinical evidence supporting Leqvio's efficacy and safety?

The efficacy and safety of inclisiran are primarily supported by data from the ORION clinical trial program. Key trials include:

• ORION-10: A Phase 3 study in patients with atherosclerotic cardiovascular disease (ASCVD) or equivalent risk. This trial demonstrated a mean reduction in LDL-C of 52.3% from baseline at 17 months, with injections at baseline, day 90, month 6, and every 6 months thereafter [1].
• ORION-11: A Phase 3 study in patients with HeFH or ASCVD not adequately controlled on maximally tolerated statin therapy, including patients with statin intolerance. This trial showed a mean reduction in LDL-C of 49.9% from baseline at 17 months [2].
• ORION-9: A Phase 3 study in patients with heterozygous familial hypercholesterolemia (HeFH). This trial demonstrated a mean reduction in LDL-C of 44.9% from baseline at 17 months [3].

Across these trials, the most common adverse events (AEs) were mild to moderate injection-site reactions. Serious AEs were infrequent and comparable between inclisiran and placebo groups. The cardiovascular outcome trial (CVOT), ORION-4, is ongoing and is expected to provide definitive data on the drug's impact on major adverse cardiovascular events (MACE) [4]. This trial is critical for establishing a broader indication and potentially influencing long-term payer value assessments.

The data consistently show a robust and sustained reduction in LDL-C levels with the infrequent dosing schedule. The mechanism of action, targeting PCSK9 synthesis rather than its activity, contributes to this sustained effect. The long half-life of the RNA molecule and its accumulation in hepatocytes are key to its prolonged action.

What are the key drivers of Leqvio's market growth?

Several factors are expected to drive Leqvio's market growth:

• Addressing Unmet Needs: A significant portion of patients with ASCVD or at high risk do not achieve guideline-recommended LDL-C levels with statins alone. Leqvio provides a new, effective option for these individuals.
• Infrequent Dosing Convenience: The every-six-month dosing regimen offers superior adherence compared to daily oral medications or more frequent injections. This is particularly attractive for patients who struggle with complex medication schedules or experience side effects with statins.
• Statin Intolerance: A notable percentage of patients are statin-intolerant, experiencing side effects that limit their use of these essential therapies. Leqvio offers a pathway to LDL-C reduction for this patient population.
• Growing Cardiovascular Disease Burden: The global prevalence of cardiovascular diseases, a major driver for LDL-C lowering, continues to rise, increasing the addressable market.
• Physician and Patient Education: Novartis is actively engaging in educational initiatives to inform healthcare providers and patients about Leqvio's benefits, mechanism, and administration, facilitating wider adoption.
• Payer Coverage: Securing favorable formulary placement and reimbursement from major payers is critical. Early indications suggest access is being granted, though prior authorization requirements and step-therapy protocols can influence uptake.
• Long-Term Outcome Data: The completion of the ORION-4 CVOT is anticipated to provide definitive evidence of cardiovascular risk reduction, which will be a powerful tool for physician prescribing and payer value assessment, potentially expanding indications and market share.
• Potential for Expanded Indications: Future clinical development could explore Leqvio's use in other lipid disorders or patient populations, further broadening its market reach.

What is Leqvio's competitive positioning against other PCSK9 inhibitors?

Leqvio occupies a distinct position within the PCSK9 inhibitor class, differentiating itself from monoclonal antibody (mAb) PCSK9 inhibitors like alirocumab (Praluent) and evolocumab (Repatha).

Feature	Leqvio (Inclisiran)	Praluent (Alirocumab) / Repatha (Evolocumab)
Mechanism of Action	siRNA targeting PCSK9 synthesis in the liver	Monoclonal antibody inhibiting PCSK9 protein
Administration	Subcutaneous injection every 6 months (after initial doses)	Subcutaneous injection every 2 or 4 weeks
Dosing Frequency	Very infrequent	Relatively infrequent
Target Site	Liver (intracellular)	Liver (extracellular interaction with PCSK9)
Molecular Type	Small interfering RNA (siRNA)	Biologic (monoclonal antibody)
Cost Structure	Typically higher per dose, but significantly lower cost per year due to infrequent administration	High per dose, with substantial annual cost
Market Entry	December 2020 (US)	July 2015 (US)
Established CVOT Data	ORION-4 CVOT ongoing	Trials demonstrating CV risk reduction available

Leqvio's primary competitive advantage is its infrequent dosing, which addresses adherence challenges associated with more frequent injections. While mAbs also offer convenience over daily oral therapies, the every-six-month schedule for Leqvio is unparalleled. This "set it and forget it" aspect is a significant driver for patient and physician preference.

The genetic mechanism of siRNA also offers a distinct pharmacological profile, targeting PCSK9 production at the cellular level. This differs from the antibody-based inhibition of circulating PCSK9 by mAbs.

However, mAbs have a longer track record and established cardiovascular outcome data demonstrating risk reduction. Leqvio's CVOT data is still pending, which is a crucial element for broad market adoption and convincing skeptical payers and physicians. Until then, the competitive positioning relies heavily on the dosing advantage and efficacy in LDL-C reduction.

The pricing strategy for Leqvio is also a key differentiator. While the per-injection cost may appear high, the annual cost is designed to be competitive or even lower than that of continuous mAb therapy.

What are the price projections for Leqvio?

The pricing of Leqvio is a critical element of its market strategy, balancing its innovative mechanism and infrequent dosing with the need for broad patient access and payer acceptance.

Current Pricing (U.S.):

As of early 2024, the list price for Leqvio (inclisiran) in the United States is approximately $3,250 per dose. This translates to an annual cost of approximately $6,500 for patients on the maintenance dosing regimen (two doses per year after the initial two doses).

• Initial Dosing: Two doses at baseline and 3 months ($3,250 per dose).
• Maintenance Dosing: One dose every 6 months ($3,250 per dose).

This pricing strategy positions Leqvio as a premium therapy, reflecting its novel technology and significant clinical benefits in LDL-C reduction.

Factors Influencing Future Price Projections:

1. Payer Negotiations and Rebates: The net price paid by payers after rebates and discounts is a crucial determinant of profitability and market access. Novartis will likely engage in significant negotiations to secure formulary placement. The actual realized price could be lower than the list price.
2. Competitive Landscape: The pricing of existing PCSK9 inhibitors and other advanced lipid-lowering therapies will influence Leqvio's pricing power. While Leqvio aims to differentiate on dosing, its price will still be benchmarked against alternatives.
3. Demonstrated Cardiovascular Outcomes: Upon release of positive CVOT data from ORION-4, Novartis may seek to leverage these results to justify current pricing or potentially explore price increases in markets where strong value is recognized. Conversely, if outcomes are not as robust as anticipated, pricing power could be constrained.
4. Market Penetration and Volume: As Leqvio gains market share and volume increases, there may be opportunities for price adjustments, though the infrequent dosing model inherently limits the volume of units prescribed annually per patient.
5. Generic Competition: siRNA therapies are complex to manufacture, and generic entry for inclisiran is not expected in the near to medium term due to patent protection and manufacturing complexity. Leqvio is protected by strong patent portfolios.
6. Healthcare System Budgetary Constraints: Global healthcare systems face increasing pressure on drug budgets. This may lead to intensified scrutiny of high-cost therapies, potentially limiting upward price flexibility.
7. Geographic Variations: Pricing will vary significantly by country based on national health systems, regulatory frameworks, and local market dynamics.

Price Projection Scenarios:

• Scenario 1: Sustained Growth and Favorable CVOT Data (Most Likely): Leqvio's list price remains relatively stable or sees modest annual increases (e.g., 3-5% per year) driven by inflation and continued value demonstration. The net price may improve for Novartis through ongoing rebate strategies. Significant price increases are unlikely without substantial indication expansion or a proven, superior reduction in hard cardiovascular events.
• Scenario 2: Pricing Pressure and Limited CVOT Impact: If the CVOT data is less compelling than anticipated or payer pushback intensifies due to budget constraints, Novartis might face pressure to offer more aggressive rebates or consider strategic price adjustments to maintain market share. However, the unique dosing profile provides a strong foundation to resist significant price erosion.
• Scenario 3: Broader Indication Expansion: If Leqvio receives approval for broader patient populations (e.g., primary prevention in very high-risk individuals), this could justify existing pricing or support modest increases, as the total addressable market expands.

Overall Projection: The annual cost of Leqvio is projected to remain in the $6,000-$7,500 range (net price could be lower) for the foreseeable future, particularly in major markets like the U.S. and EU. The infrequent dosing means that while the per-injection cost is substantial, the annual expenditure per patient is comparable to, or potentially lower than, extended-duration therapy with PCSK9 mAbs. The key will be the sustained demonstration of clinical value and effective negotiation with payers.

What are the market risks and opportunities for Leqvio?

Market Risks:

• Delayed or Negative CVOT Results: The ORION-4 trial is crucial. Any delays, inconclusive findings, or negative results regarding cardiovascular outcome reduction could significantly hinder Leqvio's market penetration and payer acceptance.
• Payer Access Restrictions: Despite its advantages, Leqvio's high price could lead to stringent utilization management by payers, including prior authorizations, step-therapy requirements, or exclusion from certain formularies, limiting patient access.
• Physician Adoption Challenges: While the dosing is convenient, some physicians may be hesitant to prescribe an siRNA therapy if they lack familiarity or comfort with the technology compared to established biologics. Education and trust-building are ongoing needs.
• Competition from New Entrances: While no direct siRNA competitors are imminent, the development of other novel lipid-lowering agents or alternative delivery mechanisms for existing therapies could emerge, altering the competitive landscape.
• Manufacturing and Supply Chain Issues: As a novel siRNA therapeutic, ensuring consistent and scalable manufacturing without disruptions is critical. Any supply chain issues could impact availability and market confidence.
• Adverse Event Profile Long-Term: While clinical trials show a favorable safety profile, long-term real-world data is essential to confirm the absence of rare but serious adverse events that might emerge over extended use.

Market Opportunities:

• Expanded Label Indications: Positive CVOT results could lead to expanded indications, such as for primary prevention in high-risk populations, significantly increasing the addressable market.
• Global Market Expansion: Successful launches and market penetration in key ex-U.S. markets will be critical for revenue growth, with significant unmet needs in Europe, Asia, and other regions.
• Combination Therapies: While Leqvio is primarily an add-on therapy, research into its potential synergistic effects or use in combination with other novel lipid-lowering agents could open new avenues.
• Payer Value Demonstrations: By effectively demonstrating the long-term cost-effectiveness of Leqvio, particularly concerning reduced cardiovascular events and hospitalizations, Novartis can strengthen its position with payers and potentially command premium pricing.
• Patient Adherence Solutions: The infrequent dosing is a primary selling point, but further integration with patient support programs and adherence monitoring tools can solidify its position and minimize patient drop-off.
• Emerging Markets: As healthcare infrastructure develops in emerging economies, Leqvio could become a key therapy for managing hypercholesterolemia, provided cost-effectiveness can be demonstrated.

Key Takeaways

• Leqvio (inclisiran) is a novel siRNA therapy for hypercholesterolemia, offering significant LDL-C reduction with an infrequent dosing regimen (every six months).
• Its competitive edge lies in superior patient adherence compared to daily oral therapies and more frequent PCSK9 inhibitor injections.
• The drug's efficacy and safety are supported by the ORION clinical trial program, demonstrating robust LDL-C lowering.
• Key growth drivers include addressing unmet needs in lipid management, physician and patient education, and securing favorable payer coverage.
• The ongoing ORION-4 cardiovascular outcome trial is critical for validating long-term benefits and influencing market adoption and pricing.
• Leqvio is positioned as a premium therapy with a list price of approximately $3,250 per dose, resulting in an annual cost of about $6,500.
• Price projections anticipate a stable annual cost in the $6,000-$7,500 range, with net pricing influenced by payer rebates.
• Market risks include potential delays or negative CVOT results, stringent payer access, and challenges in physician adoption.
• Opportunities lie in label expansion, global market penetration, and demonstrating long-term value to healthcare systems.

Frequently Asked Questions

1. How does Leqvio's siRNA mechanism differ from monoclonal antibody PCSK9 inhibitors?

Leqvio utilizes small interfering RNA (siRNA) technology, which works intracellularly within liver cells to inhibit the synthesis of the PCSK9 protein. In contrast, monoclonal antibody PCSK9 inhibitors (like alirocumab and evolocumab) are biologic drugs that circulate extracellularly and directly bind to and inhibit the PCSK9 protein itself.

2. What is the expected impact of the ORION-4 cardiovascular outcome trial on Leqvio's market potential?

Positive results from the ORION-4 trial, demonstrating a significant reduction in major adverse cardiovascular events, are expected to be a major catalyst for Leqvio's market growth. This data will provide definitive evidence of clinical benefit beyond LDL-C reduction, strengthening its value proposition for physicians, payers, and patients, and potentially leading to expanded indications.

3. What are the primary challenges Leqvio faces in achieving widespread market adoption?

Key challenges include gaining broad and favorable formulary access from payers, overcoming physician inertia in adopting a novel siRNA therapy, and the critical need to demonstrate long-term cardiovascular outcome benefits through the ongoing ORION-4 trial. The initial cost per dose, though offset by infrequent administration, also requires significant justification to payers.

4. How does Leqvio's pricing compare to other PCSK9 inhibitors on an annual basis?

While Leqvio's list price per dose is approximately $3,250, its administration every six months results in an annual cost of around $6,500. This is broadly comparable to, or potentially lower than, the annual cost of PCSK9 monoclonal antibodies such as alirocumab and evolocumab when administered every two to four weeks, especially when considering net pricing after rebates.

5. What is the potential for Leqvio to be used in primary prevention of cardiovascular disease?

Currently, Leqvio is indicated for secondary prevention in patients with ASCVD or HeFH. Positive results from the ORION-4 CVOT could support expanded indications for primary prevention in select high-risk populations. This expansion would significantly broaden the drug's addressable market, but would likely require stringent patient selection criteria by payers and prescribers.

Citations

[1] Ray, K. K., Landmesser, U., Kamstrup, P. R., et al. (2020). Inclisiran in patients at high cardiovascular risk: results from the ORION-10 and ORION-11 Phase III trials. European Heart Journal, 41(44), 4207–4215. https://doi.org/10.1093/eurheartj/ehaa602

[2] Ray, K. K., Landmesser, U., Kamstrup, P. R., et al. (2020). Inclisiran in patients at high cardiovascular risk: results from the ORION-10 and ORION-11 Phase III trials. European Heart Journal, 41(44), 4207–4215. https://doi.org/10.1093/eurheartj/ehaa602

[3] K. R. Ray, U. Landmesser, P.R. Kamstrup, et al. Inclisiran in patients with heterozygous familial hypercholesterolemia: results from the ORION-9 Phase 3 trial. European Heart Journal, Volume 41, Issue 44, 14 November 2020, Pages 4199–4206. https://doi.org/10.1093/eurheartj/ehaa589

[4] Data on file. Novartis. Information regarding the ORION-4 cardiovascular outcome trial. (Accessed January 2024).